Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics has completed the acquisition of monoclonal antibody related technology owned by Molecular Discoveries or MDC.
Subscribe to our email newsletter
The technology acquired under the MDC agreement and now owned by the company consists of a platform technology referred to by MDC as DIAAD for the potentially rapid discovery of monoclonal antibodies to detect and treat cancer and other chronic diseases and certain monoclonal antibody candidates for the potential detection and treatment of multiple myeloma, small cell lung, pancreatic and ovarian cancers.
The company is planning to start the initial phase of development of a diagnostic or prognostic product for small cell lung cancer and a therapeutic product for the treatment of small cell lung and pancreatic cancers, based upon the acquired proprietary monoclonal antibody candidates.
As contemplated by the MDC agreement, the company has entered into a consulting agreement with Cohava Gelber concurrently with the company’s acquisition of the monoclonal antibody related technology from MDC under which she will provide certain consulting services to the company on a part-time basis in connection with its development of the acquired technology during the ten-month period from the closing of the acquisition.